Naslov
Serum endothelial lipase, lipids and inflammatory markers in acute heart failure patients with metabolic syndrome ; Clinical Medical Science - Research Abstract

Autori
Potočnjak, Ines ; Degoricija, Vesna

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
PhD Programme Biomedicine and Health Sciences PhD Day 2015 Abstract Book / Jakopović, Marko ; Lacković, Zdravko (ur.) / Jakopović, Marko ; Lacković, Zdravko - Zagreb : Medicinska naklada, 2015, 52-52

ISBN
978-953-176-715-6

Skup
University of Zagreb School of Medicine PhD Day 2014

Mjesto i datum
Zagreb, Hrvatska, 22.05.2015

Vrsta sudjelovanja
Poster

Vrsta recenzije
Nije recenziran

Ključne riječi
heart failure ; metabolic syndrome ; lipase ; lipids ; markers

Sažetak
INTRODUCTION: Heart failure (HF) is defined as an abnormality of cardiac structure or function lesion leading to failure of the heart to deliver oxygen at a rate commensurate with the requirements of the metabolizing tissues, despite normal filling pressures. Metabolic syndrome (MS) is a tendency of concomitant risk factors to group: central obesity, elevated serum triglycerides, lowered HDL-cholesterol, glucose intolerance and hypertension. AIMS: Aim is to investigate whether elevated serum level of endothelial lipase, inflammatory markers and lipid profile can predict worse outcome in patients with AHF and overlapping MS. MATERIAL AND METHODS: Study was performed as observational, prospective study on AHF pts recruited from the Emergency Department (ED) from January 2014 to January 2015. Participants were divided in two groups depending on presence of MS and compared according to levels of lipids and biomarkers. Pts were treated by standard protocol for AHF by ESC Guidelines. Study was approved by local Ethics committee. Pts’ history, clinical presentation, diagnostic procedures and laboratory tests were recorded. Additionally, serum biochemical analysis will be performed at Medical University Graz, Austria. RESULTS: Analysis included data for 100 pts presenting with AHF. Interestingly there were 53% female pts and 47% male, average age 73 years. Most common clinical presentation of AHF was acute worsening of chronic HF. Unexpectedly, 90% of pts had high (III or IV) New York Heart Association (NYHA) Functional Classification. Increased BMI was observed for 70% of pts, 40% were classified as obese with BMI >30 kg/m2, 23 of them were male. It was observed that 89% pts had hypertension, 54% diabetes mellitus, 42% hypercholesterolaemia, 40% hyperlipidaemia and 30% anemia. Remarkably, 59% of investigated pts had MS, equally by gender. Average cholesterol level was 4.11 (mmol/L), 4.12 for pts with MS, 4.08 for pts without MS. Average HDL level for pts with MS was 0.943, 1.05 for patients without MS, average triglyceride level was 1.22 (mmol/L), 1.33 for pts with MS, 1.05 for pts without MS. 30-day mortality was 15%. Clinical improvement was most common recorded outcome. CONCLUSION/DISCUSION: The results should determine investigated increased laboratory markers as predictors of morbidity and mortality. MS is important concomitant factor in development of AHF. Excitingly, pts in our study had highly elevated BMI, NYHA score and overlapping MS. The results of this research offer MS as treatment focus for improving outcome of AHF pts. STATEMENT: The authors declare that they have no conflict of interest. The external financial support was recieved from collaboration with Institute of Molecular Biology and Biochemistry, Center of Molecular Medicine, Medical University Graz, Austria (Austrian Science Foundation (FWF ; grant) 2013-2016).

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA